In the context of cancer, high ANXA5 expression has been associated with poor outcome in gliomas (Zhong et al., 2021), hepatocarcinomas (Sun et al., 2018), bladder (Wu et al., 2021), colorectal (Xue et al., 2009) and cutaneous squamous cell carcinomas (Shapanis et al., 2021). Here, ANXA5 is linked to cancer.